CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04+0.00 (0.00%)
Close on Nov 13, 2026Market cap $444.52MP/E –Yield –
CytomX Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
CytomX Therapeutics's ebitda for the twelve months ending Jun 30, 2019 was -$94.46M. For fiscal 2018 it was -$75.99M. The highest annual figure on record is -$14.30M in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | -$75.99M | – |
| FY2017 | Dec 31, 2017 | -$44.61M | – |
| FY2016 | Dec 31, 2016 | -$57.85M | – |
| FY2015 | Dec 31, 2015 | -$32.00M | – |
| FY2014 | Dec 31, 2014 | -$28.98M | – |
| FY2013 | Dec 31, 2013 | -$14.30M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2019 | Jun 30, 2019 | -$30.60M | – |
| Q1 FY2019 | Mar 31, 2019 | -$15.95M | – |
| Q4 FY2018 | Dec 31, 2018 | -$25.20M | – |
| Q3 FY2018 | Sep 30, 2018 | -$22.70M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.83M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.25M | – |
| Q4 FY2017 | Dec 31, 2017 | -$843.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$10.55M | – |
| Q2 FY2017 | Jun 30, 2017 | -$25.00M | – |
| Q1 FY2017 | Mar 31, 2017 | -$8.22M | – |
| Q4 FY2016 | Dec 31, 2016 | -$13.74M | – |
See a number that looks wrong?